Baird initiated coverage of Haemonetics (HAE) with an Outperform rating and $87 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics participates in a conference call with JPMorgan
- Haemonetics Reports Balanced Earnings with Growth and Challenges
- Haemonetics price target lowered to $105 from $115 at Raymond James
- Haemonetics Reports Mixed Fiscal 2025 Results
- Haemonetics: Buy Rating Affirmed Amid Strong Q4 Performance and Margin Improvements